iifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Vivo Bio Tech executes a deal with Andhra Pradesh Med Tech Zone to set up new facility; Stock jumps over 6%

31 Jan 2022 , 11:37 AM

Vivo Bio Tech Ltd has informed that it has executed a lease deed with Andhra Pradesh Med Tech Zone Limited for setting up a new facility at Andhra Pradesh Med Tech Zone (AMTZ) Campus, Pragati Maidan, Visakhapatnam, Andhra Pradesh.

According to the filing, Vivo currently doesn’t have capacity in large animals. The new facility adds Pigs and Canines to Vivo’s small animal portfolio and this new facility, when fully functional can hold upto 178 large animals.

Further, the complete facility has been taken over by Vivo. By end of March, vivo is looking at operationalizing 25% of the capacity by end of FY 22-23, complete facility will be operational.

The additional investment like cages, lab equipment, accreditation costs, animals, Human resources will be needed in the next few quarters. Total monthly expenditure Rs30 Lacs (fixed) from March-22 and overall additional investment of Rs2.5cr will be further needed, said Company.

"This new acquisition will complete Biology portfolio of Vivo. Currently Vivo is offering services related to In-vitro studies, In-vivo studies, Physico- chemical studies, Regulatory and non-regulatory toxicology, Pharmacology, ADME, DMPK studies and sale of SPF rats and mice, Guinea Pigs and Rabbits and diagnostic services. The new addition will add medical device testing, DMPK, regulatory and nonregulatory toxicology testing services on large animals", the company further  added.

At around 11:26 AM, Vivo Bio Tech was trading at Rs69.80 apiece up by Rs4.15 or 6.32% on the BSE.

Related Tags

  • capital expansion
  • debt raise
  • equity market
  • news
  • Vivo Bio Tech Ltd
  • Vivo Bio Tech Ltd shares
  • Vivo Bio Tech Ltd stocks
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

closeIcon

Get better recommendations & make better investments

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp